<DOC>
	<DOCNO>NCT00034606</DOCNO>
	<brief_summary>The purpose study measure tumor response rate three schedule Alimta ( LY231514 ) combination gemcitabine patient locally advance metastatic non small cell lung cancer receive prior chemotherapy regimen .</brief_summary>
	<brief_title>Comparing 3 Schedules Alimta Plus Gemzar</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Diagnosis nonsmall lung cancer No prior chemotherapy Able care self An ongoing infection Pregnancy breast feed Other serious medical condition Cancer spread brain Inability take folic acid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>cancer</keyword>
	<keyword>neoplasm</keyword>
	<keyword>non-small</keyword>
	<keyword>chemotherapy</keyword>
</DOC>